Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Why Moderna Stock Surged Today - Yahoo Finance

Clinical trial results Regulatory approval AI-generated analysis

πŸ“ˆ Moderna shares jumped over 14% on Friday after reports of a major new NIH cancer research initiative.

πŸ”¬ The NIH plans to fast-track cancer treatment research in December, aiming to replicate early pandemic vaccine success.

🀝 The new public-private partnership will combine resources from healthcare companies and nonprofits to accelerate discoveries.

🎯 Initial research focus includes pancreatic, liver, colorectal cancers, and pediatric tumors using AI and mRNA tech.

πŸ’‰ Moderna's co-developed therapy intismeran showed success in extending progression-free survival for high-risk melanoma patients.

⚑ Positive clinical results are expected to accelerate Moderna's development timelines and potential profit delivery.

πŸ“‰ The Motley Fool Stock Advisor recently excluded Moderna from their top 10 stocks list for long-term growth.

Bullish Signals
  • Shares of Moderna jumped more than 14% on Friday following reports of a major new cancer research initiative.
  • The NIH plans to fast-track cancer treatment research in December, aiming to replicate the success of early-stage Covid-19 vaccine development.
  • A new public-private partnership will unite researchers and resources from various healthcare companies to accelerate scientific discoveries.
  • Advances in AI and mRNA technology are enabling doctors to design treatments tailored to each patient's immune system.
  • Moderna and Merck announced that their co-developed investigational mRNA-based therapy, intismeran, increased the time before cancer returned or spread in patients with high-risk melanoma.
  • Encouraging clinical trial results are prompting healthcare leaders to devote more resources to cancer research.
  • The new initiative could help accelerate Moderna's development timelines, potentially enabling the biotech to deliver new therapies to patients and profits to shareholders faster than previously expected.
Full Analysis
Moderna (NASDAQ:MRNA) shares surged more than 14% on Friday following reports of a major new cancer research initiative. The National Institutes of Health plans to launch a campaign in December to fast-track cancer treatment research, aiming to replicate the success seen with early-stage Covid-19 vaccine development. This public-private partnership will unite researchers and resources from various healthcare companies and nonprofits to accelerate scientific discoveries. Initial efforts will focus on pancreatic, liver, colorectal cancers, and pediatric tumors, leveraging advances in AI and mRNA technology to design personalized immune system treatments. The initiative aligns with recent positive clinical data where Moderna's co-developed therapy, intismeran, combined with Merck's Keytruda, extended progression-free survival for high-risk melanoma patients. These developments are expected to accelerate Moderna's development timelines, potentially enabling faster delivery of new therapies and profits to shareholders. Despite the bullish news driving the stock price higher, The Motley Fool notes that Moderna was not included in their current list of top 10 stocks for investors, citing a specific analyst team recommendation rather than general market consensus.